205 related articles for article (PubMed ID: 29886522)
1. Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study.
Calabrese JR; Jin N; Johnson B; Such P; Baker RA; Madera J; Hertel P; Ottinger J; Amatniek J; Kawasaki H
Int J Bipolar Disord; 2018 Jun; 6(1):14. PubMed ID: 29886522
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study.
McIntyre RS; Such P; Yildirim M; Madera-McDonough J; Zhang Z; Larsen F; Harlin M
Curr Med Res Opin; 2023 Jul; 39(7):1021-1030. PubMed ID: 37272079
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
[TBL] [Abstract][Full Text] [Related]
4. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
J Affect Disord; 2018 Feb; 227():649-656. PubMed ID: 29174738
[TBL] [Abstract][Full Text] [Related]
5. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry PP; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
J Affect Disord; 2018 Dec; 241():425-432. PubMed ID: 30145513
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; Salzman PM; McQuade RD; Nyilas M; Carson WH
J Clin Psychiatry; 2017 Mar; 78(3):324-331. PubMed ID: 28146613
[TBL] [Abstract][Full Text] [Related]
8. Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment.
Madera J; Such P; Zhang P; Baker RA; Grande I
Neuropsychiatr Dis Treat; 2019; 15():2325-2338. PubMed ID: 31616148
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study.
Peters-Strickland T; Baker RA; McQuade RD; Jin N; Eramo A; Perry P; Johnson BR; Duca A; Sanchez R
NPJ Schizophr; 2015; 1():15039. PubMed ID: 27336044
[TBL] [Abstract][Full Text] [Related]
10. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study.
Citrome L; Such P; Yildirim M; Madera-McDonough J; Beckham C; Zhang Z; Larsen F; Harlin M
J Clin Psychiatry; 2023 Sep; 84(5):. PubMed ID: 37672016
[No Abstract] [Full Text] [Related]
12. Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies.
Madera JJ; Such P; Zhao C; Baker RA
Neuropsychiatr Dis Treat; 2019; 15():1593-1604. PubMed ID: 31354275
[No Abstract] [Full Text] [Related]
13. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
Naber D; Baker RA; Eramo A; Forray C; Hansen K; Sapin C; Peters-Strickland T; Nylander AG; Hertel P; Nitschky Schmidt S; Loze JY; Potkin SG
Schizophr Res; 2018 Feb; 192():205-210. PubMed ID: 28433498
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
[TBL] [Abstract][Full Text] [Related]
15. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
[TBL] [Abstract][Full Text] [Related]
16. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.
Kane JM; Sanchez R; Baker RA; Eramo A; Peters-Strickland T; Perry PP; Johnson BR; Tsai LF; Carson WH; McQuade RD; Fleischhacker WW
Clin Schizophr Relat Psychoses; 2015; 9(2):79-87. PubMed ID: 25711509
[TBL] [Abstract][Full Text] [Related]
17. Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder.
Weisler RH; Kalali AH; Cutler AJ; Gazda TD; Ginsberg L
Psychiatry (Edgmont); 2008 May; 5(5):49-60. PubMed ID: 19727252
[TBL] [Abstract][Full Text] [Related]
18. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.
McElroy SL; Suppes T; Frye MA; Altshuler LL; Stanford K; Martens B; Leverich GS; Post RM; Keck PE
J Affect Disord; 2007 Aug; 101(1-3):275-81. PubMed ID: 17229469
[TBL] [Abstract][Full Text] [Related]
19. Initiation of aripiprazole once-monthly in patients with schizophrenia.
Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
[TBL] [Abstract][Full Text] [Related]
20. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
Vieta E; Owen R; Baudelet C; McQuade RD; Sanchez R; Marcus RN
Curr Med Res Opin; 2010 Jun; 26(6):1485-96. PubMed ID: 20429835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
